Forest Laboratories announces new appointments to its executive team

16 December 2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments to its executive leadership team. The appointments are part of Forest’s plans to broaden the organization as part of Project Rejuvenate.

“Today we are announcing an important step to rejuvenate our company by creating the first Forest executive team with broad leadership responsibilities, a sharp focus and clear accountability for driving sustainable growth,” said Brent Saunders, chief executive and president of Forest Laboratories.

David Solomon, senior vice president of corporate development and strategic planning will become senior advisor to the chief executive responsible for business development and alliance management on a transitional basis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK